|
POSSIBLE POTENTIATION OF BRADYCARDIA, SINUS ARREST AND AV BLOCK
|
INCREASE RISK OF INDUCING VENTRICULAR ARRHYTHMIAS
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION MAY PRODUCE ELECTROCARDIOGRAPHIC ABNORMALITIES AND INCREASE RISK OF CONVULSIONS, IF USED IN SEVERE MALARIA, MEFLOQUINE ADMINISTRATION SHOULD BE DELAYED AT LEAST 12 HRS. AFTER THE LAST DOSE
|
CO-ADMINISTRATION MAY PRODUCE ELECTROCARDIOGRAPHIC ABNORMALITIES AND INCREASE RISK OF CONVULSIONS, IF USED IN SEVERE MALARIA, MEFLOQUINE ADMINISTRATION SHOULD BE DELAYED AT LEAST 12 HRS. AFTER THE LAST DOSE
|
CO-ADMINISTRATION MAY PRODUCE ELECTROCARDIOGRAPHIC ABNORMALITIES AND INCREASE RISK OF CONVULSIONS, IF USED IN SEVERE MALARIA, MEFLOQUINE ADMINISTRATION SHOULD BE DELAYED AT LEAST 12 HRS. AFTER THE LAST DOSE
|
CO-ADMINISTRATION MAY PRODUCE ELECTROCARDIOGRAPHIC ABNORMALITIES AND INCREASE RISK OF CONVULSIONS, IF USED IN SEVERE MALARIA, MEFLOQUINE ADMINISTRATION SHOULD BE DELAYED AT LEAST 12 HRS. AFTER THE LAST DOSE
|
CO-ADMINISTRATION MAY PRODUCE ELECTROCARDIOGRAPHIC ABNORMALITIES AND INCREASE RISK OF CONVULSIONS, IF USED IN SEVERE MALARIA, MEFLOQUINE ADMINISTRATION SHOULD BE DELAYED AT LEAST 12 HRS. AFTER THE LAST DOSE
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION MAY REDUCE SEIZURE CONTROL BY LOWERING THE PLASMA LEVELS OF ANTICONVULSANT; DOSAGE OF ANTICONVULSANT MAY NEED TO BE ADJUSTED
|
CO-ADMINISTRATION MAY REDUCE SEIZURE CONTROL BY LOWERING THE PLASMA LEVELS OF ANTICONVULSANT; DOSAGE OF ANTICONVULSANT MAY NEED TO BE ADJUSTED
|
CO-ADMINISTRATION MAY REDUCE SEIZURE CONTROL BY LOWERING THE PLASMA LEVELS OF ANTICONVULSANT; DOSAGE OF ANTICONVULSANT MAY NEED TO BE ADJUSTED
|
CO-ADMINISTRATION MAY REDUCE SEIZURE CONTROL BY LOWERING THE PLASMA LEVELS OF ANTICONVULSANT; DOSAGE OF ANTICONVULSANT MAY NEED TO BE ADJUSTED
|
CO-ADMINISTRATION MAY REDUCE SEIZURE CONTROL BY LOWERING THE PLASMA LEVELS OF ANTICONVULSANT; DOSAGE OF ANTICONVULSANT MAY NEED TO BE ADJUSTED
|
CO-ADMINISTRATION MAY REDUCE SEIZURE CONTROL BY LOWERING THE PLASMA LEVELS OF ANTICONVULSANT; DOSAGE OF ANTICONVULSANT MAY NEED TO BE ADJUSTED
|
CO-ADMINISTRATION MAY REDUCE SEIZURE CONTROL BY LOWERING THE PLASMA LEVELS OF ANTICONVULSANT; DOSAGE OF ANTICONVULSANT MAY NEED TO BE ADJUSTED
|